Literature DB >> 11339351

Immunoglobulin in the control of complement action.

M M Frank1, V D Miletic, H Jiang.   

Abstract

Complement is a critical element of innate immunity, protecting individuals from a wide variety of microbial infections. This group of proteins is responsible for many features of inflammation and tissue damage. Because of its ability to mediate autoimmune tissue damage and to destroy host tissues, it is under tight regulation with many circulating and cell-membrane-bound complement regulatory proteins. The function of much of the circulating immunoglobulin has never been defined. We have advanced the hypothesis that one function of circulating immunoglobulin is to down-regulate complement attack on host tissues in the presence of anti-self antibody. The data to support this hypothesis are reviewed. The data are consistent with the suggestion that one mechanism of action of intravenous immunoglobulin, used to treat patients with a variety of autoimmune diseases, is prevention of complement-mediated attack on host tissues.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11339351     DOI: 10.1385/IR:22:2-3:137

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   4.505


  30 in total

Review 1.  Control of the complement system.

Authors:  M K Liszewski; T C Farries; D M Lublin; I A Rooney; J P Atkinson
Journal:  Adv Immunol       Date:  1996       Impact factor: 3.543

2.  High dose intravenous immunoglobulin does not affect complement-bacteria interactions.

Authors:  E Wagner; J L Platt; M M Frank
Journal:  J Immunol       Date:  1998-02-15       Impact factor: 5.422

3.  The treatment of Kawasaki syndrome with intravenous gamma globulin.

Authors:  J W Newburger; M Takahashi; J C Burns; A S Beiser; K J Chung; C E Duffy; M P Glode; W H Mason; V Reddy; S P Sanders
Journal:  N Engl J Med       Date:  1986-08-07       Impact factor: 91.245

4.  Anti-idiotypic suppression of autoantibodies to factor VIII (antihaemophilic factor) by high-dose intravenous gammaglobulin.

Authors:  Y Sultan; M D Kazatchkine; P Maisonneuve; U E Nydegger
Journal:  Lancet       Date:  1984-10-06       Impact factor: 79.321

5.  Inhibition of complement-mediated red cell lysis by immunoglobulins is dependent on the IG isotype and its C1 binding properties.

Authors:  T E Mollnes; K Høgåsen; B F Hoaas; T E Michaelsen; P Garred; M Harboe
Journal:  Scand J Immunol       Date:  1995-05       Impact factor: 3.487

6.  Regulation of complement activity by immunoglobulin. I. Effect of immunoglobulin isotype on C4 uptake on antibody-sensitized sheep erythrocytes and solid phase immune complexes.

Authors:  V D Miletic; C G Hester; M M Frank
Journal:  J Immunol       Date:  1996-01-15       Impact factor: 5.422

7.  Classical pathway complement activation in Kawasaki syndrome.

Authors:  T Kohsaka; J Abe; T Asahina; N Kobayashi
Journal:  J Allergy Clin Immunol       Date:  1994-02       Impact factor: 10.793

8.  High doses of intravenous immunoglobulin do not affect the recognition phase of the classical complement pathway.

Authors:  M Basta; L F Fries; M M Frank
Journal:  Blood       Date:  1991-08-01       Impact factor: 22.113

9.  Mechanism of therapeutic effect of high-dose intravenous immunoglobulin. Attenuation of acute, complement-dependent immune damage in a guinea pig model.

Authors:  M Basta; P Kirshbom; M M Frank; L F Fries
Journal:  J Clin Invest       Date:  1989-12       Impact factor: 14.808

10.  IgG bearing covalently bound C3b has enhanced bactericidal activity for Escherichia coli 0111.

Authors:  K A Joiner; L F Fries; M A Schmetz; M M Frank
Journal:  J Exp Med       Date:  1985-09-01       Impact factor: 14.307

View more
  14 in total

Review 1.  Therapeutic potential of complement modulation.

Authors:  Eric Wagner; Michael M Frank
Journal:  Nat Rev Drug Discov       Date:  2009-12-04       Impact factor: 84.694

Review 2.  Intravenous immunoglobulins--understanding properties and mechanisms.

Authors:  A Durandy; S V Kaveri; T W Kuijpers; M Basta; S Miescher; J V Ravetch; R Rieben
Journal:  Clin Exp Immunol       Date:  2009-12       Impact factor: 4.330

Review 3.  Adverse effects of treatment with intravenous immunoglobulins for neurological diseases.

Authors:  Matthias Wittstock; Uwe K Zettl
Journal:  J Neurol       Date:  2006-09       Impact factor: 4.849

4.  Incubation Environment Affects Immune System Development in a Turtle with Environmental Sex Determination.

Authors:  Steven Freedberg; Timothy J Greives; Michael A Ewert; Gregory E Demas; Nancy Beecher; Craig E Nelson
Journal:  J Herpetol       Date:  2008-09-01       Impact factor: 1.577

Review 5.  B cells and humoral immunity in atherosclerosis.

Authors:  Dimitrios Tsiantoulas; Cody J Diehl; Joseph L Witztum; Christoph J Binder
Journal:  Circ Res       Date:  2014-05-23       Impact factor: 17.367

Review 6.  Dysfunction of innate immunity and associated pathology in neonates.

Authors:  Anna Petrova; Rajeev Mehta
Journal:  Indian J Pediatr       Date:  2007-02       Impact factor: 5.319

Review 7.  Therapeutic regulation of complement in patients with renal disease - where is the promise?

Authors:  Johua M Thurman
Journal:  Clin Nephrol       Date:  2012-05       Impact factor: 0.975

8.  Effectiveness of Intravenous Immunoglobulin Plus Plasmapheresis on Antibody-mediated Rejection or Thrombotic Microangiopathy in Iranian Kidney Transplant Recipient.

Authors:  Simin Dashti-Khavidaki; Lida Shojaie; Amin Hosni; Mohammad Reza Khatami; Atefeh Jafari
Journal:  Nephrourol Mon       Date:  2015-05-23

9.  Dose-dependent inhibition of demyelination and microglia activation by IVIG.

Authors:  Meike Winter; Christine Baksmeier; Julia Steckel; Sumanta Barman; Manish Malviya; Melanie Harrer-Kuster; Hans-Peter Hartung; Norbert Goebels
Journal:  Ann Clin Transl Neurol       Date:  2016-09-23       Impact factor: 4.511

Review 10.  Treatment of chronic inflammatory demyelinating polyneuropathy: from molecular bases to practical considerations.

Authors:  Paolo Ripellino; Thomas Fleetwood; Roberto Cantello; Cristoforo Comi
Journal:  Autoimmune Dis       Date:  2014-01-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.